Investigation of the Relationship Between Periodontitis and Sleep Quality
Trial Parameters
Brief Summary
This project aims to investigate the relationship between periodontitis and sleep quality. Its originality lies in evaluating the association between periodontal status and sleep quality together with salivary interleukin-6 (IL-6), interleukin-6 (IL-10) IL-10, and pentraxin-3 levels. In particular, examining the relationship of sleep quality with biological, psychological, and lifestyle factors through periodontitis and salivary IL-6, IL-10, and pentraxin-3 levels has not been previously studied in the literature. Methodologically, periodontal status will be determined through clinical examination; participants' Pittsburgh Sleep Quality Index and Multidimensional Fatigue Inventory scores will be recorded; and salivary IL-6, IL-10, and pentraxin-3 levels will be measured. The obtained data will be compared using statistical analyses to determine the strength of the relationship between periodontitis severity and sleep quality. From a management perspective, the project will be conducted following approval from the ethics committee. In terms of broader impact, the results are expected to scientifically demonstrate the relationship between periodontitis and sleep quality, contribute to the adoption of a holistic health approach in clinical practice, and increase public health awareness. Additionally, the project is expected to provide a foundation for future research on the relationship between oral health and quality of life.
Eligibility Criteria
Inclusion Criteria: * systemically healthy, * clinical diagnosis of periodontitis, * clinical diagnosis of periodontal health Exclusion Criteria: * history of regular use of systemic antibiotics, anti-inflammatory, or antioxidant drugs (previous 6 months); * nonsurgical periodontal treatment (previous 6 months); * surgical periodontal treatment (previous 12 months); * presence of \<20 teeth; * current medications affecting gingival health (calcium channel blockers, phenytoin, cyclosporine, and hormone replacement therapy); * diabetes diagnosis; rheumatoid arthritis diagnosis; and pregnancy, lactating, or excessive alcohol consumption.